Brief: Nordic Nanovector Granted US Patent

Thor Medical ASA

05/05/2020 06:34

May 5 (Reuters) - Nordic Nanovector ASA  NANOV.OL :
    * NORDIC NANOVECTOR ANNOUNCES US PATENT GRANTED COVERING THE
USE
OF BETALUTIN® TO SENSITISE B-CELL CANCER CELLS TO CD20
IMMUNOTHERAPY
    * ANNOUNCES GRANT OF US PATENT COVERING USE OF BETALUTIN
((177)LU-SATETRAXETAN-LILOTOMAB) FOR SENSITISING CD37-POSITIVE
B-CELL CANCER CELLS BEFORE TREATMENT WITH CD20 IMMUNOTHERAPY
    * PATENT STRENGTHENS CO'S OVERALL PATENT ESTATE AROUND USE
OF
BETALUTIN® IN COMBINATION WITH OTHER DRUGS THAT TARGET ANTIGENS
PRESENTED ON SURFACE OF TUMOUR CELLS IN PATIENTS WITH B-CELL
MALIGNANCIES, SUCH AS NON-HODGKIN'S LYMPHOMA (NHL)

Source text for Eikon:  ID:nWkr91VN8T 
Further company coverage:  NANOV.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))